We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Santhera: Drug Misses Endpoints in Friedreich’s Ataxia Trial
Santhera: Drug Misses Endpoints in Friedreich’s Ataxia Trial
May 26, 2010
Santhera has missed primary and secondary endpoints in a Phase III study of its Friedreich’s ataxia treatment Catena/Sovrima.